var data={"title":"Flecainide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Flecainide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6201?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=flecainide-drug-information\" class=\"drug drug_general\">see &quot;Flecainide: Drug information&quot;</a> and <a href=\"topic.htm?path=flecainide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Flecainide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708772\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mortality:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide was included in the National Heart Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had an MI more than 6 days but less than 2 years previously. An excessive mortality or nonfatal cardiac arrest rate was seen in patients treated with flecainide compared with that seen in patients assigned to a carefully matched placebo-treated group. This rate was 5.1% for flecainide and 2.3% for the matched placebo. The average duration of treatment with flecainide in this study was 10 months.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The applicability of the CAST results to other populations (eg, those without recent MI) is uncertain, but at present, it is prudent to consider the risks of Class &Iota;C agents (including flecainide), coupled with the lack of any evidence of improved survival, generally unacceptable in patients without life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ventricular proarrhythmic effects in patients with atrial fibrillation/flutter:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">A review of the world literature revealed reports of 568 patients treated with oral flecainide for paroxysmal atrial fibrillation/flutter (PAF). Ventricular tachycardia was experienced in 0.4% of these patients. Of 19 patients in the literature with chronic atrial fibrillation (CAF), 10.5% experienced ventricular tachycardia (VT) or ventricular fibrillation (VF). Flecainide is not recommended for use in patients with CAF. Case reports of ventricular proarrhythmic effects in patients treated with flecainide for atrial fibrillation/flutter have included increased premature ventricular contractions (PVCs), VT, VF, and death.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">As with other Class &Iota; agents, patients treated with flecainide for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing the atrial rate. A paradoxical increase in the ventricular rate also may occur in patients with atrial fibrillation who receive flecainide. Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171518\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Flecainide;</li>\n      <li>Tambocor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052761\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiarrhythmic Agent, Class I-C</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12674627\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Supraventricular tachycardia (SVT), suppression:</b> Very limited data available; optimal dose not established: Flecainide has been used alone and in combination with digoxin, propranolol, or sotalol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>BSA-directed dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: Oral: 70 to 100 mg/m<sup>2</sup>/day divided every 12 hours. Dosing should be titrated based on response and serum concentrations (Price 2002). Dosing based on a retrospective review of 10 patients, including 6 neonates (age range: 1 to 17 days), with refractory SVT who were treated with flecainide and sotalol. The median starting dose of flecainide was 70 mg/m<sup>2</sup>/day in 2 divided doses; the median dose required to reach therapeutic trough goal of 200 to 800 ng/mL was 100 mg/m<sup>2</sup>/day (dose range: 70 to 150 mg/m<sup>2</sup>/day). Suppression of SVT was achieved in all patients; no proarrhythmic activity was reported (Price 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Weight-directed dosing: </i>\n      <b>Note:</b> In clinical trials, this dose was initiated after acute SVT controlled with IV flecainide (not available in US) (Ferlini 2009; O'Sullivan 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: Oral: 2 mg/kg/day divided every 12 hours; titrate to clinical response, monitor serum concentration; usual dose range in infants and children is 3 to 6 mg/kg/day (Park 2014); doses &gt;8 mg/kg/day have been associated with a higher incidence of proarrhythmic effects in children (Perry 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosing based on a prospective and retrospective study; in both studies, acute SVT was initially controlled with IV flecainide (not available in US) and then converted to preventative oral therapy (Ferlini 2009; O'Sullivan 1995). The prospective study enrolled 20 neonates (mean PNA: 11.5 &plusmn; 11.07 days; mean GA: 36.8 &plusmn; 3 weeks; mean birthweight: 2.8 &plusmn; 0.8 kg) with paroxysmal SVT without any structural heart disease; following acute restoration of sinus rhythm, oral flecainide was administered to suppress further SVT episodes; a mean dose of 3.35 &plusmn; 1.35 mg/kg/day completely controlled SVT in 17 neonates; 3 patients required the addition of propranolol; this study did not report resultant serum concentrations (Ferlini 2009). In a retrospective analysis of 39 neonates and infants treated with digoxin and/or flecainide to prevent the recurrence of SVT (median PNA at treatment: 12 days; range: 1 to 330 days; neonates: n=32), 25 of the patients received flecainide at an initial dose of 6 to 8 mg/kg/day divided every 12 hours and titrated based on response and serum concentrations; final doses ranged from 3.2 to 13.5 mg/kg/day and successfully suppressed SVT in 96% of patients. The authors noted high variability in serum concentrations with initial dosing (0.23 to 1.14 mcg/mL) (O'Sullivan 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052755\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=flecainide-drug-information\" class=\"drug drug_general\">see &quot;Flecainide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Arrhythmias: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: BSA-directed dosing: Use caution with dose titration, as small change in dose may result in disproportionate increase in plasma concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &le;6 months: Oral: Initial: 50 mg/m<sup>2</sup>/day divided every 8 to 12 hours; may titrate dose at 4-day intervals; maximum daily dose: 200 mg/m<sup>2</sup>/<b>day</b>; higher doses have been associated with an increased risk of proarrhythmic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;6 months, Children, and Adolescents: Oral: Initial: 100 mg/m<sup>2</sup>/day divided every 8 to 12 hours; may titrate dose at 4-day intervals; maximum daily dose: 200 mg/m<sup>2</sup>/<b>day</b>; higher doses have been associated with an increased risk of proarrhythmic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: Weight-based dosing: Limited data available; dosing regimens variable: Infants, Children, and Adolescents: Oral: Initial: 1 to 3 mg/kg/day divided every 8 hours; may titrate dose at 4-day intervals; usual maintenance range: 3 to 6 mg/kg/day (Park 2014); an average effective dose of 4 mg/kg/day was reported in an expert analysis of literature and clinical experience (Perry 1992); maximum daily dose: 8 mg/kg/<b>day</b> (Perry 1992); higher doses have been associated with an increased risk of proarrhythmic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Atrial fibrillation or flutter (pharmacological cardioversion):</b> Outpatient: &quot;Pill-in-the-pocket&quot; dose: Oral: 200 mg (patient weight &lt;70 kg), 300 mg (weight &ge;70 kg). May not repeat in &le;24 hours (AHA/ACC/HRS [January 2014]; Alboni 2004). <b>Note:</b> An initial inpatient conversion trial should have been successful before sending patient home on this approach. Patient must be taking an AV nodal-blocking agent (eg, beta-blocker, nondihydropyridine calcium channel blocker) prior to initiation of antiarrhythmic.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ventricular arrhythmias (prevention):</b> Oral: Initial: 100 mg every 12 hours, increase by 50 mg twice daily at 4-day intervals; maximum: 400 mg/<b>day</b>. Some patients inadequately controlled with or intolerant to dosing every 12 hours may require dosing every 8 hours. <b>Note:</b> Initiate therapy in a hospital setting in patients with sustained ventricular tachycardia. Use of higher initial doses and more rapid dosage adjustments have resulted in an increased incidence of proarrhythmic events and congestive heart failure, particularly during the first few days. Do not use a loading dose. Use very cautiously in patients with history of congestive heart failure or myocardial infarction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardias (prevention):</b> Oral: Initial: 50 mg every 12 hours; increase by 50 mg twice daily at 4-day intervals; maximum daily dose: 300 mg/<b>day</b>. The AHA/ACC/HRS atrial fibrillation guidelines recommend a maximum total daily dose of 400 mg (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> <b>Note: </b>Not dialyzable (~1%): Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;35 mL/minute/1.73 m<sup>2</sup>: Initial: 100 mg every 12 hours; consider obtaining plasma concentrations to guide dosage adjustments. Dose increases should be made very cautiously at intervals &gt;4 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;35 mL/minute/1.73 m<sup>2</sup>: Initial: 50 mg every 12 hours or 100 mg once daily; obtain plasma concentrations to guide dosage adjustments. Dose increases should be made very cautiously at intervals &gt;4 days and serum trough concentrations monitored frequently. In patients with end stage renal disease, renal clearance is very low as compared to patients with moderate renal impairment and the plasma half-life may extend up to 58 hours (Conard 1984).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Removal by hemodialysis is negligible (only ~1% of an oral dose).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, elimination from the plasma may be slower in patients with hepatic impairment. Use with caution; obtain plasma concentrations to guide dosage adjustments. Dose increases should be made very cautiously at intervals &gt;4 days and serum concentrations monitored frequently. Frequent plasma level monitoring is required in patients with severe hepatic impairment; if unavailable, use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171494\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 100 mg, 150 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171480\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052766\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer around-the-clock to promote less variation in peak and trough serum levels. May be administered in children and adults without regard to food; in infants receiving milk or milk based formulas, avoid concurrent administration with feedings; monitor serum concentrations and decrease the dose when the diet changes to a decreased consumption of milk</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28806220\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) in a tight, light-resistant container</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052765\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention and suppression of documented life-threatening ventricular arrhythmias (ie, sustained ventricular tachycardia); prevention of symptomatic, disabling supraventricular tachycardias in patients without structural heart disease (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171570\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flecainide may be confused with fluconazole </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tambocor [DSC] may be confused with Pamelor, Temodar, tamoxifen, Tamiflu</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171568\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest pain, edema, palpitation, proarrhythmic, sinus node dysfunction, syncope, tachycardia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, ataxia, depression, dizziness, fatigue, fever, headache, hypoesthesia, insomnia, malaise, nervousness, paresis, somnolence, tinnitus, vertigo </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, nausea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Paresthesias, tremor, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ocular: Blurred vision, diplopia, visual disturbances </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Alopecia, alters pacing threshold, amnesia, angina, AV block, bradycardia, bronchospasm, CHF, corneal deposits, depersonalization, euphoria, exfoliative dermatitis, granulocytopenia, heart block, increased P-R, leukopenia, metallic taste, neuropathy, paradoxical increase in ventricular rate in atrial fibrillation/flutter, paresthesia, photophobia, pneumonitis, pruritus, QRS duration, swollen lips/tongue/mouth, tardive dyskinesia, thrombocytopenia, urinary retention, urticaria, ventricular arrhythmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171502\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to flecainide or any component of the formulation; pre-existing second- or third-degree AV block or with right bundle branch block when associated with a left hemiblock (bifascicular block) (except in patients with a functioning artificial pacemaker); cardiogenic shock; concurrent use of ritonavir</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">According to the American College of Cardiology/American Heart Association/European Society of Cardiology, the use of flecainide is considered contraindicated in patients with structural heart disease (ACC/AHA/ESC [Blomstrom-Lundqvist 2003]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171484\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proarrhythmic effects: <b>[US Boxed Warning]: Proarrhythmic effects (including increased premature ventricular contractions, ventricular tachycardia, ventricular fibrillation, and death) have been reported in patients with atrial fibrillation/fibrillation who received flecainide; use is not recommended for patients with chronic atrial fibrillation.</b> Flecainide can cause new or worsened supraventricular or ventricular arrhythmias in all patients; effect is dose-related. Patients with sustained ventricular tachycardia and serious underlying heart disease are at an increased risk; initiation of therapy should occur in a hospital setting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atrial fibrillation (chronic): Use is not recommended in patients with chronic atrial fibrillation due to an increased risk of life-threatening ventricular arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atrial flutter: Appropriate use: <b>[US Boxed Warning]: When treating atrial flutter, 1:1 atrioventricular conduction may occur; pre-emptive negative chronotropic therapy (eg, digoxin, beta-blockers) may lower the risk.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction disturbances: Dose-related increases in PR and QRS intervals occur. If second- or third-degree AV block, or right bundle branch block associated with a left hemiblock occur, flecainide therapy should be discontinued unless a temporary or implanted ventricular pacemaker is in place to ensure an adequate ventricular rate. Use with extreme caution in patients with sick sinus syndrome; treatment with flecainide may result in sinus bradycardia, sinus pause, or sinus arrest.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart disease: Avoid use in patients with heart failure; may precipitate or exacerbate condition, increase the risk of proarrhythmia, and contribute to an increased risk of mortality (ACCF/AHA [Yancy 2013]). According to the manufacturer, use with extreme caution in patients with structural heart disease as the risk of death and cardiac events may be increased. According to the ACC/AHA/HRS, flecainide should be avoided in patients with structural or ischemic heart disease (ACC/AHA/HRS [Page 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with significant hepatic impairment; benefit should outweigh risk. Consider careful monitoring during initiation of therapy.  Dose titration should occur only after steady state has been achieved (&ge;4 days after initiation). Frequent plasma level monitoring is required in patients with severe hepatic impairment; if unavailable, use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with significant renal impairment. Frequent plasma level monitoring is required in patients with severe renal impairment; if unavailable, use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Small changes in dose may lead to disproportionate increases in plasma concentrations in pediatric patients. Following initiation of therapy or changes in dose, obtain plasma trough concentrations and ECG once steady state has been achieved (&gt;5 doses after initiation or change); regular monitoring of trough concentrations and ECG is recommended by the manufacturer during the first year of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CAST trial: <b>[US Boxed Warning]: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide.</b> An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. The risks of class 1C agents and the lack of improved survival make use in patients without life-threatening arrhythmias generally unacceptable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pacemakers: Use with caution in patients with permanent pacemakers or temporary pacing wires; can increase endocardial pacing thresholds and suppress ventricular escape rhythms. Do not use in patients with existing poor thresholds or nonprogrammable pacemakers unless suitable pacing rescue is available. The pacing threshold in patients with pacemakers should be determined at baseline, 1 week after initiation and at regular intervals thereafter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171556\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171489\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13302&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the QTc-prolonging effect of Flecainide. Amiodarone may increase the serum concentration of Flecainide. Management: Decrease flecainide dose by 50% in the presence of amiodarone.  Monitor for adverse effects of flecainide and consider monitoring for elevated serum concentrations during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Flecainide. Management: Canadian labeling recommends avoiding this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of Flecainide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Flecainide.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Flecainide may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May increase the serum concentration of Flecainide. Management: Concurrent use of ritonavir-boosted fosamprenavir with flecainide is contraindicated.  The use of non-ritonavir-boosted fosamprenavir with flecainide is not specifically contraindicated but should only be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: May increase the serum concentration of Flecainide. Management: Monitor clinical response to flecainide closely.  Dose adjustment may be necessary.  Canadian mirabegron labeling recommends restricting the maximum adult mirabegron dose to 25 mg/day in patients receiving flecainide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pindolol: Flecainide may enhance the bradycardic effect of Pindolol. The negative inotropic effects of Pindolol may also be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Flecainide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May enhance the arrhythmogenic effect of Flecainide. Saquinavir may increase the serum concentration of Flecainide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Bicarbonate: May diminish the arrhythmogenic effect of Flecainide. Sodium Bicarbonate may increase the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Lactate: May increase the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May enhance the adverse/toxic effect of Flecainide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Flecainide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tromethamine: May increase the serum concentration of Flecainide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May enhance the adverse/toxic effect of Flecainide. In particular, this combination may significantly impair myocardial contractility and AV nodal conduction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171514\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Clearance may be decreased in patients following strict vegetarian diets due to urinary pH &ge;8. Milk may interfere with the absorption of flecainide (Russell 1989; Thompson 2012). Management: Dose reduction should be considered when milk is removed from the diet (eg, during weaning or bouts of gastroenteritis). Plasma trough flecainide levels should be monitored during major changes in dietary milk intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171490\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13386419\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Flecainide is recommended in the treatment of fetal tachycardia determined to be SVT. Flecainide may be also used for the ongoing management of SVT in highly symptomatic pregnant patients. The lowest effective dose is recommended; avoid use during the first trimester if possible (Page [ACC/AHA/HRS 2015]). Additional guidelines are available for management of cardiovascular diseases during pregnancy (ESG [Regitz-Zagrosek 2011]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052760\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG, blood pressure, pulse, periodic serum concentrations after at least 5 doses when doses are started or changed or when dietary changes due to maturation or concurrent illness occur, liver enzymes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052764\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic trough: 0.2 to 1 mcg/mL (SI: 0.4 to 2 micromoles/L). <b>Note</b>: Pediatric patients may respond at the lower end of the recommended therapeutic range (0.2 to 0.5 mcg/mL) but up to 0.8 mcg/mL may be required. <b>Note:</b> Hemolysis during blood sampling may cause a falsely elevated flecainide concentration (Vento 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171483\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Class Ic antiarrhythmic; slows conduction in cardiac tissue by altering transport of ions across cell membranes; causes slight prolongation of refractory periods; decreases the rate of rise of the action potential without affecting its duration; increases electrical stimulation threshold of ventricle, His-Purkinje system; possesses local anesthetic and moderate negative inotropic effects</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171501\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Nearly complete; decreased when administered with milk</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Newborns: Up to &le;29 hours; 3 months: 11 to 12 hours; 12 months: 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: ~8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 12 to 15 years: ~11 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~20 hours (range: 12 to 27 hours); increased in patients with heart failure (NYHA Class III) or renal dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~3 hours (range: 1 to 6 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (30% [range: 10% to 50%] as unchanged drug); feces (5%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171500\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>20 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 20 mg/mL oral liquid suspension may be made from tablets and one of three different vehicles (cherry syrup, a 1:1 mixture of Ora-Sweet and Ora-Plus, or a 1:1 mixture of Ora-Sweet SF and Ora-Plus). Crush twenty-four 100 mg tablets in a mortar and reduce to a fine powder. Add 20 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light.&rdquo; Stable for 60 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated.</p>\n    <div class=\"reference\">Allen LV, Erickson III MA. Stability of baclofen, captopril, diltiazem, hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm</i>. 1996;53:2179-2184.<span class=\"pubmed-id\">8879325</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171504\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Flecainide Acetate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $201.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $357.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $434.32</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171505\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Almarytm (IT);</li>\n      <li>Apocard (ES, PT);</li>\n      <li>Aristocor (AT);</li>\n      <li>Diondel (AR, CL, UY);</li>\n      <li>Flecadura (DE);</li>\n      <li>Flecaine (FR, LB, VN);</li>\n      <li>Flecaine LP (FR);</li>\n      <li>Flecatab (AU, TW);</li>\n      <li>Flekainid (SK);</li>\n      <li>Flekalnidu (UA);</li>\n      <li>Fulcard (KR);</li>\n      <li>Tambocor (AE, AU, BE, BF, BH, BJ, BM, CH, CI, CL, CR, CY, DE, DK, DO, EE, EG, ET, FI, GB, GH, GM, GN, GR, GT, HK, HN, IE, IL, IQ, IR, IS, JO, JP, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PH, QA, RO, SA, SC, SD, SE, SL, SN, SV, SY, TH, TN, TW, TZ, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Tambocor CR (NZ, PH);</li>\n      <li>Tambocor Retard (NO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alboni P, Botto GL, Baldi N, et al, &quot;Outpatient Treatment of Recent-Onset Atrial Fibrillation With the 'Pill-in-the-Pocket' Approach,&quot; <i>N Engl J Med</i>, 2004, 351(23):2384-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/15575054/pubmed\" target=\"_blank\" id=\"15575054\">15575054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blomstrom-Lundqvist C, Scheinman MM, Aliot EM; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines. Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of PatientsWith Supraventricular Arrhythmias). <i>Circulation.</i> 2003;108(15):1871-1909.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/14557344/pubmed\" target=\"_blank\" id=\"14557344\">14557344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conard GJ, Ober RE. Metabolism of flecainide. <i>Am J Cardiol</i>. 1984;53(5):41B-51B.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/6364769/pubmed\" target=\"_blank\" id=\"6364769\">6364769</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al; ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197. doi: 10.1093/eurheartj/ehr218.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenrich AL Jr, Perry JC, and Friedman RA, &ldquo;Flecainide and Amiodarone: Combined Therapy for Refractory Tachyarrhythmias in Infants,&rdquo; <i>J Am Coll Cardiol</i>, 1995, 25(5):1195-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/7897134/pubmed\" target=\"_blank\" id=\"7897134\">7897134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferlini M, Colli AM, Bonanomi C, et al, &quot;Flecainide as First-Line Treatment for Supraventricular Tachycardia in Newborns,&quot;<i> J Cardiovasc Med (Hagerstown)</i>, 2009, 10(5):372-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/19300276/pubmed\" target=\"_blank\" id=\"19300276\">19300276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flecainide acetate [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals, Inc; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/24682347 /pubmed\" target=\"_blank\" id=\"24682347 \">24682347 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Musto B, Cavallaro C, Musto A, et al, &ldquo;Flecainide Single Oral Dose for Management of Paroxysmal Supraventricular Tachycardia in Children and Young Adults,&rdquo; <i>Am Heart J</i>, 1992, 124(1):110-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/1615792/pubmed\" target=\"_blank\" id=\"1615792\">1615792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Sullivan JJ, Gardiner HM, and Wren C, &quot;Digoxin or Flecainide for Prophylaxis of Supraventricular Tachycardia in Infants?&quot; <i>J Am Coll Cardiol</i>, 1995, 26(4):991-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/7560629/pubmed\" target=\"_blank\" id=\"7560629\">7560629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115. doi: 10.1016/j.jacc.2015.08.856.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK, ed. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. St Louis, MO: Elsevier/Mosby; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry JC and Garson A Jr. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing<i>. </i><i>Am Heart J. </i>1992; 124(6):1614-1621.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/1462922/pubmed\" target=\"_blank\" id=\"1462922\">1462922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry JC, McQuinn RL, Smith RT Jr, et al, &ldquo;Flecainide Acetate for Resistant Arrhythmias in the Young: Efficacy and Pharmacokinetics,&rdquo; <i>J Am Coll Cardiol</i>, 1989, 14(1):185-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/2500470/pubmed\" target=\"_blank\" id=\"2500470\">2500470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Price JF, Kertesz NJ, Snyder CS, Friedman RA, Fenrich AL. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children &lt;1 year of age. <i>J Am Coll Cardiol</i>. 2002;39(3):517-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/11823091/pubmed\" target=\"_blank\" id=\"11823091\">11823091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Priestley KA, Ladusans EJ, Rosenthal E, et al, &ldquo;Experience With Flecainide for the Treatment of Cardiac Arrhythmias in Children,&rdquo; <i>Eur Heart J</i>, 1988, 9(12):1284-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/3147891/pubmed\" target=\"_blank\" id=\"3147891\">3147891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russell GA and Martin RP, &ldquo;Flecainide Toxicity,&rdquo; <i>Arch Dis Child</i>, 1989, 64(6):860-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/2505692/pubmed\" target=\"_blank\" id=\"2505692\">2505692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson B, Mangat J, Barton C, Hawcutt DB. Decreased milk drinking causing flecainide toxicity in an older child. <i>BMJ Case Rep</i>. 2012;pii: bcr0220125810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/22729333/pubmed\" target=\"_blank\" id=\"22729333\">22729333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vento M, Tudela BF, Escrig R, S&aacute;enz P, S&aacute;nchez A, Cano A. Haemolysis alters plasma flecainide levels in newborn infants. <i>Acta Paediatr</i>. 2007;96(3):466-468.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/17407483/pubmed\" target=\"_blank\" id=\"17407483\">17407483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2013;62(16):e147-e239.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/23747642/pubmed\" target=\"_blank\" id=\"23747642\">23747642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeigler V, Gillette PC, Ross BA, et al, &ldquo;Flecainide for Supraventricular and Ventricular Arrhythmias in Children and Young Adults,&rdquo; <i>Am J Cardiol</i>, 1988, 62(10 Pt 1):818-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flecainide-pediatric-drug-information/abstract-text/3138905/pubmed\" target=\"_blank\" id=\"3138905\">3138905</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13302 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708772\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F171518\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052761\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12674627\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052755\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171494\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F171480\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052766\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F28806220\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052765\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171570\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171568\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171502\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171484\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F171556\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F171489\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F171514\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F171490\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13386419\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052760\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1052764\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171483\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F171501\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F171500\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F171504\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F171505\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13302|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=flecainide-drug-information\" class=\"drug drug_general\">Flecainide: Drug information</a></li><li><a href=\"topic.htm?path=flecainide-patient-drug-information\" class=\"drug drug_patient\">Flecainide: Patient drug information</a></li></ul></div></div>","javascript":null}